ALFA Finder
11:57 IST
NSE
Earnings Call
Sai Life Science Earnings Call Transcript: Key Takeaways
Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.
Sai Life Science Ltd
- Share price
- ₹1,910.70
- Market cap
- ₹40,618 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 108.0×Sector 43.8×
- Promoter holding
- 34.50%-0.03% QoQ
- FII holding
- 19.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Employee Stock Options 11Other Announcement 5Earnings Call 5Financial Results 4Results Update 3Board Meeting Date 2Annual General Meeting 2Management Change 1Legal & Regulatory 1Business Update 1Board Meeting Outcome 1Annual Report 1
Time
5 announcements with these filters
00:15 IST
NSE
Earnings Call
Sai Life Science Investor Presentation: Key Takeaways
H1 FY27 revenue ₹1,213 Cr (+17% YoY), EBITDA ₹335 Cr (28% margin), PAT ₹172 Cr (+19%). Q2 revenue ₹659 Cr (+23%). Strategy: integrated CRDMO, larger strategic pharma engagements, ₹621 Cr H1 capex.
13:48 IST
BSE
Earnings Call
Sai Life Science Investor Presentation: Key Takeaways
Sai Life Sciences delivered strong Q1FY27 performance with revenue of ₹554 Cr, up 12% YoY, and PAT of ₹73 Cr, up 22% YoY, driven by growth in CRO and CDMO segments.
- Call
- Guides 20% growth
14:10 IST
BSE
Earnings Call
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences reported robust FY26 performance with 29% revenue growth and 109% PAT growth, driven by deepening engagement with 19 of top 25 global pharma companies.
14:24 IST
BSE
Earnings Call
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences delivered strong FY26 performance with 29% revenue growth and 56% EBITDA growth, driven by expansion in CDMO and CRO segments and improved operating leverage.